Safety and efficacy of two anti-acne/anti-aging treatments in subjects with photodamaged skin and mild to moderate acne vulgaris

  • 60min
  • May. 2022
  • Supported by
  • SkinCeuticals

Abstract

Background: Although reliable prevalence data are not available, adult acne is thought to be somewhat common, and it is no unusual for patients to have acne as well as easy signs of skin aging. A nove anti-acne/anti-aging formulation (Treatment A) has been developed for daily use by patients to address both signs of skin aging and facial acne vulgarisms. The novel, non-prescription formulation includes several ingredient shown to target factors underlying the pathogenesis of acne vulgarisms while also addressing multiple components in the pathophysiology of skin aging.

Methods: A blinded, randomised, split-face study was conducted to evaluate and compare the tolerability and efficacy of the novel anti-acne/anti-aging product in subjects with photo damaged skin and acne vulgarisms relative to tretinoin cream 0.025% (Treatment B). All subjects were also given supportive skincare, consisting of a cleanser, moisturiser, and sunscreen. Each treatment were assessed fir its effects on subjects' appearence, lesion count reductions, and tolerability.

Results: Treatment A statistically significantly greater improvements in skin tone evenness, skin tone clarity, and blemishes and blotchiness. There were also statistically greater reductions in total lesion count for acne patients on the side of the face teated with Treatment A compared to The treatment B; Treatment A was also associated with early (day 2) improvement in skin tone evenness and clarity, tactile skin smoothness, and blemishes and blotchiness. Both treatments demonstrated favorable tolerability.

Conclusion: The novel topical anti-aging/anti-acne therapy (Treatment A) within a comprehensive skin care regimen of cleanser, moisturiser and sunscreen may maximise efficacy and tolerability, and contribute to our armamentarium for treating both photodamage and acne at the same time.

Journal of Drugs and Dermatology 2012;11(6):737-740


Leon H. Kircik, MD; Amanda Dahl, BS; Margarita Yatskayer, MS; Susana Raab, BS; Christian Oresajo, PhD